Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 65 | 2024 | 21029 | 2.630 |
Why?
|
Mastectomy, Segmental | 19 | 2024 | 972 | 2.100 |
Why?
|
Mastectomy | 19 | 2022 | 1832 | 2.020 |
Why?
|
Mammaplasty | 7 | 2024 | 1240 | 1.360 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 9 | 2022 | 936 | 1.160 |
Why?
|
Carcinoma, Ductal, Breast | 11 | 2017 | 1096 | 0.880 |
Why?
|
Carcinoma, Lobular | 7 | 2017 | 489 | 0.740 |
Why?
|
Breast | 4 | 2018 | 1963 | 0.670 |
Why?
|
Neoadjuvant Therapy | 7 | 2019 | 2821 | 0.630 |
Why?
|
Staff Development | 1 | 2020 | 229 | 0.610 |
Why?
|
Receptor, erbB-2 | 7 | 2018 | 2554 | 0.590 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2019 | 3530 | 0.580 |
Why?
|
Preoperative Care | 5 | 2016 | 2255 | 0.570 |
Why?
|
Salaries and Fringe Benefits | 1 | 2019 | 258 | 0.560 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2018 | 733 | 0.540 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2016 | 586 | 0.530 |
Why?
|
SEER Program | 10 | 2019 | 1530 | 0.520 |
Why?
|
Receptors, Progesterone | 4 | 2016 | 1130 | 0.450 |
Why?
|
Receptors, Estrogen | 8 | 2018 | 2210 | 0.440 |
Why?
|
Magnetic Resonance Imaging | 13 | 2022 | 36286 | 0.420 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2012 | 102 | 0.390 |
Why?
|
Neoplasm Staging | 17 | 2020 | 11152 | 0.390 |
Why?
|
Income | 1 | 2019 | 1875 | 0.370 |
Why?
|
Socioeconomic Factors | 5 | 2019 | 7805 | 0.340 |
Why?
|
Leiomyosarcoma | 1 | 2012 | 424 | 0.320 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2021 | 1791 | 0.310 |
Why?
|
Aged | 51 | 2024 | 169143 | 0.310 |
Why?
|
Female | 71 | 2024 | 391246 | 0.300 |
Why?
|
Medicare | 8 | 2022 | 6785 | 0.300 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2019 | 9278 | 0.290 |
Why?
|
Umbilicus | 1 | 2005 | 39 | 0.260 |
Why?
|
Aged, 80 and over | 25 | 2019 | 58980 | 0.250 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2007 | 198 | 0.250 |
Why?
|
Physicians | 2 | 2022 | 4591 | 0.250 |
Why?
|
Intestinal Fistula | 1 | 2005 | 143 | 0.240 |
Why?
|
Appendix | 1 | 2005 | 110 | 0.240 |
Why?
|
United States | 29 | 2024 | 72448 | 0.240 |
Why?
|
Early Detection of Cancer | 3 | 2019 | 3202 | 0.230 |
Why?
|
Women's Health | 1 | 2014 | 2056 | 0.230 |
Why?
|
Humans | 76 | 2024 | 760613 | 0.230 |
Why?
|
Lymph Node Excision | 5 | 2021 | 1303 | 0.230 |
Why?
|
Neoplasm Invasiveness | 7 | 2016 | 3618 | 0.230 |
Why?
|
Breast Neoplasms, Male | 2 | 2016 | 221 | 0.220 |
Why?
|
Prognosis | 13 | 2024 | 29661 | 0.210 |
Why?
|
Lymphatic Metastasis | 5 | 2017 | 2943 | 0.210 |
Why?
|
Middle Aged | 41 | 2024 | 220359 | 0.210 |
Why?
|
Insulin Resistance | 3 | 2022 | 3959 | 0.210 |
Why?
|
Cimicifuga | 1 | 2022 | 5 | 0.200 |
Why?
|
Mass Screening | 3 | 2016 | 5422 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5325 | 0.200 |
Why?
|
Lymph Nodes | 4 | 2018 | 3486 | 0.190 |
Why?
|
Medical Order Entry Systems | 1 | 2007 | 522 | 0.190 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39262 | 0.190 |
Why?
|
Decision Making | 4 | 2019 | 3925 | 0.190 |
Why?
|
Healthcare Disparities | 3 | 2024 | 3386 | 0.180 |
Why?
|
Databases, Factual | 7 | 2017 | 8022 | 0.180 |
Why?
|
Appendicitis | 1 | 2005 | 674 | 0.160 |
Why?
|
Workload | 1 | 2004 | 847 | 0.160 |
Why?
|
Hemangiosarcoma | 1 | 2021 | 216 | 0.160 |
Why?
|
Seroma | 1 | 2018 | 76 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11713 | 0.150 |
Why?
|
Genetic Testing | 3 | 2020 | 3531 | 0.150 |
Why?
|
Genes, BRCA2 | 1 | 2020 | 603 | 0.140 |
Why?
|
Paget's Disease, Mammary | 1 | 2016 | 19 | 0.140 |
Why?
|
Ki-67 Antigen | 2 | 2022 | 631 | 0.140 |
Why?
|
Mammography | 4 | 2016 | 2427 | 0.140 |
Why?
|
Genetic Counseling | 1 | 2020 | 624 | 0.140 |
Why?
|
Refusal to Treat | 1 | 2016 | 45 | 0.140 |
Why?
|
Histiocytosis | 1 | 2016 | 40 | 0.130 |
Why?
|
Peer Group | 2 | 2018 | 674 | 0.130 |
Why?
|
Preoperative Period | 1 | 2018 | 555 | 0.130 |
Why?
|
Ultrasonography, Mammary | 2 | 2016 | 239 | 0.130 |
Why?
|
Adult | 30 | 2024 | 220007 | 0.130 |
Why?
|
Retrospective Studies | 17 | 2021 | 80345 | 0.130 |
Why?
|
Population Groups | 1 | 2016 | 211 | 0.120 |
Why?
|
Carcinoma | 2 | 2016 | 2331 | 0.120 |
Why?
|
Biopsy, Needle | 1 | 2019 | 1630 | 0.120 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2016 | 146 | 0.120 |
Why?
|
Taxoids | 1 | 2018 | 669 | 0.120 |
Why?
|
General Surgery | 1 | 2004 | 1678 | 0.110 |
Why?
|
Insurance Coverage | 2 | 2015 | 1939 | 0.110 |
Why?
|
Breast Diseases | 1 | 2016 | 443 | 0.110 |
Why?
|
Insurance, Health | 3 | 2024 | 2501 | 0.110 |
Why?
|
Medical Record Linkage | 1 | 2014 | 288 | 0.100 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13627 | 0.100 |
Why?
|
Employment | 1 | 2019 | 1112 | 0.100 |
Why?
|
Fee-for-Service Plans | 2 | 2014 | 705 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2015 | 12159 | 0.100 |
Why?
|
Surgical Flaps | 1 | 2020 | 1669 | 0.100 |
Why?
|
Cohort Studies | 8 | 2022 | 41337 | 0.100 |
Why?
|
Tumor Burden | 4 | 2022 | 1895 | 0.100 |
Why?
|
Pediatrics | 1 | 2007 | 3586 | 0.100 |
Why?
|
Intraoperative Care | 1 | 2015 | 768 | 0.100 |
Why?
|
Lymphedema | 1 | 2018 | 524 | 0.090 |
Why?
|
Carcinoma in Situ | 2 | 2015 | 796 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2019 | 1529 | 0.090 |
Why?
|
Leadership | 1 | 2020 | 1371 | 0.090 |
Why?
|
Fellowships and Scholarships | 1 | 2019 | 1116 | 0.090 |
Why?
|
Hospital Costs | 1 | 2017 | 976 | 0.090 |
Why?
|
Surgery, Plastic | 1 | 2017 | 643 | 0.090 |
Why?
|
Health Surveys | 3 | 2019 | 4063 | 0.090 |
Why?
|
Patient Satisfaction | 2 | 2019 | 3448 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2754 | 0.080 |
Why?
|
Risk Assessment | 3 | 2019 | 24102 | 0.080 |
Why?
|
Patient Care Planning | 1 | 2015 | 908 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2017 | 6465 | 0.080 |
Why?
|
Surgical Wound Infection | 1 | 2018 | 1527 | 0.080 |
Why?
|
Logistic Models | 4 | 2016 | 13312 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 510 | 0.080 |
Why?
|
Gamma Rays | 1 | 2009 | 317 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1060 | 0.080 |
Why?
|
Motivation | 1 | 2018 | 1993 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2012 | 1832 | 0.070 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1066 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2622 | 0.070 |
Why?
|
Treatment Outcome | 7 | 2020 | 64981 | 0.070 |
Why?
|
Life Style | 1 | 2019 | 3898 | 0.070 |
Why?
|
Pain, Postoperative | 1 | 2018 | 1720 | 0.070 |
Why?
|
Survivors | 2 | 2015 | 2375 | 0.070 |
Why?
|
Societies, Medical | 1 | 2019 | 3905 | 0.070 |
Why?
|
Health Expenditures | 2 | 2017 | 2362 | 0.070 |
Why?
|
Alcohol Drinking | 1 | 2019 | 4013 | 0.070 |
Why?
|
Perception | 1 | 2012 | 1195 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3844 | 0.060 |
Why?
|
Health Care Surveys | 2 | 2019 | 2435 | 0.060 |
Why?
|
Incidence | 4 | 2016 | 21391 | 0.060 |
Why?
|
Radionuclide Imaging | 1 | 2009 | 1975 | 0.060 |
Why?
|
Age Factors | 6 | 2019 | 18413 | 0.060 |
Why?
|
Risk Factors | 4 | 2019 | 74333 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5075 | 0.060 |
Why?
|
Brachytherapy | 1 | 2012 | 1238 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2017 | 5397 | 0.060 |
Why?
|
Internship and Residency | 1 | 2004 | 5870 | 0.060 |
Why?
|
Hospital Information Systems | 1 | 2007 | 394 | 0.060 |
Why?
|
Cost of Illness | 1 | 2014 | 1940 | 0.060 |
Why?
|
Comorbidity | 2 | 2015 | 10553 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2017 | 8552 | 0.060 |
Why?
|
Time Factors | 3 | 2019 | 40139 | 0.060 |
Why?
|
Private Sector | 1 | 2006 | 397 | 0.050 |
Why?
|
Exercise | 1 | 2019 | 5787 | 0.050 |
Why?
|
Liver Neoplasms | 2 | 2012 | 4319 | 0.050 |
Why?
|
Appendectomy | 1 | 2005 | 431 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2001 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4046 | 0.050 |
Why?
|
Axilla | 2 | 2016 | 626 | 0.050 |
Why?
|
Body Mass Index | 1 | 2019 | 12914 | 0.050 |
Why?
|
Estrogen Antagonists | 1 | 2022 | 151 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2021 | 15679 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5508 | 0.050 |
Why?
|
Reoperation | 3 | 2017 | 4289 | 0.050 |
Why?
|
Diet | 1 | 2019 | 8010 | 0.050 |
Why?
|
Male | 11 | 2020 | 359718 | 0.050 |
Why?
|
Biopsy | 1 | 2012 | 6771 | 0.050 |
Why?
|
Medication Errors | 1 | 2007 | 784 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2012 | 2531 | 0.040 |
Why?
|
Colectomy | 1 | 2005 | 692 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17790 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6316 | 0.040 |
Why?
|
Mental Health | 1 | 2013 | 3213 | 0.040 |
Why?
|
Hepatectomy | 1 | 2002 | 559 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8458 | 0.040 |
Why?
|
Attitude of Health Personnel | 2 | 2016 | 3865 | 0.040 |
Why?
|
Prospective Studies | 4 | 2017 | 54306 | 0.040 |
Why?
|
Epirubicin | 1 | 2018 | 83 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2013 | 14661 | 0.040 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 380 | 0.040 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2020 | 277 | 0.040 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2019 | 144 | 0.040 |
Why?
|
Orthopedics | 1 | 2006 | 892 | 0.040 |
Why?
|
Perioperative Period | 1 | 2018 | 264 | 0.040 |
Why?
|
Cryosurgery | 1 | 2002 | 475 | 0.030 |
Why?
|
Connecticut | 1 | 2017 | 365 | 0.030 |
Why?
|
Receptor, Insulin | 1 | 2020 | 836 | 0.030 |
Why?
|
Histiocytosis, Sinus | 1 | 2016 | 46 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2012 | 20509 | 0.030 |
Why?
|
Body Weight | 1 | 2007 | 4611 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 4312 | 0.030 |
Why?
|
Friends | 1 | 2017 | 150 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 25941 | 0.030 |
Why?
|
Radiotherapy, Conformal | 1 | 2019 | 549 | 0.030 |
Why?
|
Medically Underserved Area | 1 | 2017 | 257 | 0.030 |
Why?
|
Diagnostic Self Evaluation | 1 | 2016 | 225 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1088 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1578 | 0.030 |
Why?
|
Fluorouracil | 1 | 2018 | 1631 | 0.030 |
Why?
|
Life Expectancy | 1 | 2019 | 1247 | 0.030 |
Why?
|
Adolescent | 5 | 2016 | 87809 | 0.030 |
Why?
|
Medicaid | 1 | 2006 | 2815 | 0.030 |
Why?
|
Histocytochemistry | 1 | 2013 | 700 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2019 | 1548 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2019 | 2897 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2018 | 2222 | 0.020 |
Why?
|
Primary Prevention | 1 | 2019 | 1207 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8803 | 0.020 |
Why?
|
Paclitaxel | 1 | 2018 | 1737 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2005 | 12968 | 0.020 |
Why?
|
Physical Examination | 1 | 2016 | 1244 | 0.020 |
Why?
|
Treatment Failure | 1 | 2016 | 2647 | 0.020 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 1660 | 0.020 |
Why?
|
Physician's Role | 1 | 2017 | 918 | 0.020 |
Why?
|
Radiotherapy | 1 | 2017 | 1504 | 0.020 |
Why?
|
Postoperative Period | 1 | 2015 | 1818 | 0.020 |
Why?
|
Laparoscopy | 1 | 2002 | 2147 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2013 | 2471 | 0.020 |
Why?
|
Information Dissemination | 1 | 2017 | 1131 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1926 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8556 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2608 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2514 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2012 | 13262 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3465 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 1677 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2315 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 26179 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6831 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2019 | 3598 | 0.020 |
Why?
|
Family | 1 | 2017 | 3189 | 0.020 |
Why?
|
Health Status | 1 | 2019 | 4082 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3242 | 0.020 |
Why?
|
Health Personnel | 1 | 2019 | 3310 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 22075 | 0.020 |
Why?
|
Communication | 1 | 2019 | 3849 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11070 | 0.020 |
Why?
|
Infant | 1 | 2007 | 36053 | 0.010 |
Why?
|
Regression Analysis | 1 | 2014 | 6359 | 0.010 |
Why?
|
Calcinosis | 1 | 2013 | 1476 | 0.010 |
Why?
|
Health Policy | 1 | 2017 | 2677 | 0.010 |
Why?
|
Radiography | 1 | 2015 | 6965 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5201 | 0.010 |
Why?
|
Young Adult | 3 | 2016 | 58748 | 0.010 |
Why?
|
Quality of Life | 2 | 2017 | 13308 | 0.010 |
Why?
|
Child, Preschool | 1 | 2007 | 42056 | 0.010 |
Why?
|
Survival Analysis | 1 | 2016 | 10185 | 0.010 |
Why?
|
Ultrasonography | 1 | 2016 | 5961 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5795 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9406 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8512 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6544 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10546 | 0.010 |
Why?
|
Child | 2 | 2007 | 79799 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3985 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4279 | 0.010 |
Why?
|
Survival Rate | 1 | 2013 | 12810 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10343 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9468 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 13982 | 0.010 |
Why?
|
Concepts
(246)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_